ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Impact of Unfractionated Heparin Use on Maternal Bone Mineral Density During Pregnancy: A Retrospective Study Using AI-Assisted Radiographic Analysis.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeThis study aimed to evaluate the impact of unfractionated heparin (UFH) use during pregnancy on maternal bone mineral density (BMD) by assessing BMD in pregnant women with heparin exposure using an artificial intelligence (AI)-assisted analysis of chest radiographs.
methodsThis retrospective cohort study was conducted between April 2013 and October 2023. Pregnant women who received UFH therapy and underwent cesarean section (CS) were compared, using preoperative chest radiographs, with a control group who underwent CS without medication. Estimated BMD (eBMD) values for the lumbar spine (LS) and femoral neck (FN) were obtained via an AI-assisted diagnostic system. Statistical analyses included univariate and multivariate methods, adjusted for covariates.
resultsCompared with the control group (n = 213), the UFH group (n = 86) exhibited significantly lower eBMD values at both LS and FN. Body mass index (BMI) correlated with eBMD in both groups, with underweight participants showing significantly lower eBMD, particularly in the UFH group. Multivariate analysis identified UFH as an independent factor associated with reduced eBMD in patients with LS. No significant correlation was found between the total UFH dose and eBMD.
conclusionUFH administration during pregnancy may be associated with decreased maternal eBMD, especially in underweight women, with the LS appearing more susceptible to bone loss than the FN. The estimation system may provide a safe, accessible, and effective method for early detection and risk stratification of pregnancy-associated bone loss, supporting future clinical management in at-risk populations.
Indexed as
Identifiers
42207474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.